8-K: Cingulate Secures $12M Private Placement, Adds Board Representation

Cingulate Inc. announced a private placement raising approximately $12 million through the sale of common stock, convertible preferred stock, and warrants, with new board representation for a key investor.

Summary

• Cingulate Inc. entered into a private placement agreement on January 27, 2026, to raise approximately $12,000,000 in aggregate gross proceeds.
• The private placement includes the sale of 2,147,471 shares of common stock, 973 shares of Series A convertible preferred stock, and warrants to purchase 1,868,482 shares of common stock.
• The common stock was priced at $5.04 per share, the preferred stock has a stated value of $1,000 and a conversion price of $5.04 per share, and the warrants were priced at $0.10 per warrant share.
• The Series A convertible preferred stock carries a cumulative dividend of 12.0% per annum, payable yearly in arrears, which can be settled in cash, common stock, or accrue and compound.
• Conversion of the preferred stock and exercisability of the warrants are contingent upon obtaining stockholder approval.
• Purchasers in the private placement include certain officers, directors, and other affiliates of the company.
• Falcon Creek, a manager of one of the purchasers (Singapore Entity), is entitled to designate up to two directors to the company's Board of Directors, one immediately and one after stockholder approval.
• A non-voting Board Observer from the Singapore Entity will be appointed until stockholder approval is obtained.
• The company will file a registration statement for the resale of the securities within 60 calendar days following the closing date.
• A 180-day lock-up period applies to the purchasers, restricting the sale or transfer of the securities, with certain exceptions.
• A 24-month standstill provision limits purchasers from acquiring more than 40% of outstanding common stock, soliciting proxies, or participating in certain corporate transactions.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful capital raise providing significant funding for the company's operations. However, the potential for dilution, the need for stockholder approval, and the future overhang from the lock-up period temper the overall positive impact.

Positives

• Successfully secured approximately $12 million in gross proceeds, strengthening the company's financial position for working capital and general corporate purposes.
• The involvement of Falcon Creek, a strategic investor, and their right to board representation, suggests a vote of confidence and potential strategic guidance.
• The company's commitment to file a registration statement for resale provides a path to liquidity for the new investors.

Negatives

• The issuance of new common stock, convertible preferred stock, and warrants will result in dilution for existing shareholders.
• Full conversion of preferred stock and exercisability of warrants, as well as the designation of the second director, are subject to obtaining stockholder approval, introducing an element of uncertainty.
• The 180-day lock-up period for purchasers, while standard, means a significant block of shares could become available for sale after this period, potentially impacting market price.

Risks

• Significant dilution of existing shareholders' ownership due to the issuance of new common stock, preferred stock, and warrants.
• Failure to obtain required stockholder approval could limit the full conversion of preferred stock and exercisability of warrants, and the designation of the second director.
• The market price of the company's publicly-traded securities may be negatively impacted by future open market transactions, including short sales or derivative transactions, by purchasers after the lock-up period.
• Potential inquiries or directives from the Committee on Foreign Investment in the United States (CFIUS) or under Outbound Investment Rules, requiring cooperation and potentially mitigation agreements.
• General business risks related to compliance with various regulations, including FDA, environmental, occupational health and safety, and data privacy laws, as highlighted in the company's representations.

Future Outlook

The company intends to use the net proceeds from the private placement for working capital and general corporate purposes. It plans to file a registration statement for the resale of the newly issued securities within 60 calendar days of closing and will seek stockholder approval for the full issuance of underlying shares and the designation of the second director from Falcon Creek. The company will hold a stockholder meeting as promptly as possible to obtain this approval.

Industry Context

This capital raise is a common strategy for development-stage or growth-oriented companies, particularly in the biotechnology or pharmaceutical sector (implied by FDA mentions), to secure funding for ongoing operations, research, and development. The structure of the private placement, including convertible preferred stock and warrants, is typical for attracting institutional investors willing to take on higher risk for potential equity upside. The inclusion of board representation for a key investor like Falcon Creek often signals a more strategic partnership beyond just capital infusion.

Management Changes

Corporate Governance

Related Party Transactions

• Certain officers, directors, and other affiliates of the company are among the purchasers in the private placement.

Stakeholder Impact

• **Shareholders**: Will experience dilution from the issuance of new common stock, convertible preferred stock, and warrants. Their voting power may be affected by the need for stockholder approval for certain aspects of the transaction and the new board representation.
• **Investors (Purchasers)**: Gain equity ownership, preferred dividends, and warrants, along with significant governance rights including board representation and an observer seat. They are subject to lock-up and standstill provisions.
• **Company**: Benefits from a substantial capital infusion of $12 million, providing funds for working capital and general corporate purposes, which can support ongoing operations and strategic initiatives.
• **Management**: Gains financial flexibility to execute business plans but will operate with increased oversight from the new investor-appointed directors.

Next Steps

• Close the Private Placement and issue the securities on or before February 2, 2026.
• File a registration statement with the SEC for the resale of the Securities within 60 calendar days following the closing date.
• Hold a stockholder meeting as promptly as possible (within 60 days of proxy statement filing) to obtain approval for the issuance of underlying shares in excess of 19.99% and the designation of the second Falcon Creek Director.
• Maintain the listing of common stock on The Nasdaq Capital Market.
• Falcon Creek will designate one director to the Board on the Closing Date and a second director after stockholder approval.

Key Dates

Recommendation

The capital raise is a positive development, providing Cingulate with crucial funding for its operations. However, the significant dilution for existing shareholders, the contingency of stockholder approval for full conversion and board representation, and the potential market overhang after the 180-day lock-up period introduce uncertainties. Investors should monitor the market's reaction to the dilution, the outcome of the stockholder vote, and the company's execution of its business plan with the new capital before making further investment decisions.

Keywords

Cingulate Inc., private placement, common stock, preferred stock, warrants, capital raise, SEC filing, corporate governance, investor rights, Nasdaq, stock dilution, Falcon Creek, convertible securities